• search hit 10 of 13
Back to Result List

Evaluation of a New Recombinant Oncolytic Vaccinia Virus Strain GLV-5b451 for Feline Mammary Carcinoma Therapy

Please always quote using this URN: urn:nbn:de:bvb:20-opus-119387
  • Virotherapy on the basis of oncolytic vaccinia virus (VACV) infection is a promising approach for cancer therapy. In this study we describe the establishment of a new preclinical model of feline mammary carcinoma (FMC) using a recently established cancer cell line, DT09/06. In addition, we evaluated a recombinant vaccinia virus strain, GLV-5b451, expressing the anti-vascular endothelial growth factor (VEGF) single-chain antibody (scAb) GLAF-2 as an oncolytic agent against FMC. Cell culture data demonstrate that GLV-5b451 virus efficientlyVirotherapy on the basis of oncolytic vaccinia virus (VACV) infection is a promising approach for cancer therapy. In this study we describe the establishment of a new preclinical model of feline mammary carcinoma (FMC) using a recently established cancer cell line, DT09/06. In addition, we evaluated a recombinant vaccinia virus strain, GLV-5b451, expressing the anti-vascular endothelial growth factor (VEGF) single-chain antibody (scAb) GLAF-2 as an oncolytic agent against FMC. Cell culture data demonstrate that GLV-5b451 virus efficiently infected, replicated in and destroyed DT09/06 cancer cells. In the selected xenografts of FMC, a single systemic administration of GLV-5b451 led to significant inhibition of tumor growth in comparison to untreated tumor-bearing mice. Furthermore, tumor-specific virus infection led to overproduction of functional scAb GLAF-2, which caused drastic reduction of intratumoral VEGF levels and inhibition of angiogenesis. In summary, here we have shown, for the first time, that the vaccinia virus strains and especially GLV-5b451 have great potential for effective treatment of FMC in animal model.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Marion Adelfinger, Ivaylo Gentschev, Julio Grimm de Guibert, Stephanie Weibel, Johanna Langbein-Laugwitz, Barbara Härtl, Hugo Murua Escobar, Ingo Nolte, Nanhai G. Chen, Richard J. Aguilar, Yong A. Yu, Qian Zhang, Alexa Frentzen, Aladar A. Szalay
URN:urn:nbn:de:bvb:20-opus-119387
Document Type:Journal article
Faculties:Medizinische Fakultät / Institut für Molekulare Infektionsbiologie
Fakultät für Biologie / Theodor-Boveri-Institut für Biowissenschaften
Language:English
Parent Title (English):PLoS ONE
Year of Completion:2014
Volume:9
Issue:8
Pagenumber:e104337
Source:PLoS ONE 9(8): e104337. doi:10.1371/journal.pone.0104337
DOI:https://doi.org/10.1371/journal.pone.0104337
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 616 Krankheiten
Tag:antibodies; cancer treatment; carcinomas; cell cultures; enzyme-linked immunoassays; oncolytic viruses; vaccinia virus; viral replication
Release Date:2015/10/21
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung